A Controlled Trial of Amantadine in Drug-Induced Extrapyramidal Disorders
- 1 May 1976
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 33 (5) , 599-602
- https://doi.org/10.1001/archpsyc.1976.01770050055008
Abstract
• Presently marketed antiparkinsonism drugs are potent anticholinergic agents that, while effective in treating extrapyramidal symptoms (EPS), also are productive of or can exacerbate a number of side effects associated with psychotropic drugs. Some of these include gastrointestinal disturbances, visual difficulties, and tardive dyskinesia. A double-blind study was carried out to assess the efficacy (and adverse effects) of amantadine hydrochloride—an agent without appreciable anticholinergic activity—for the treatment of drug-induced EPS. Amantadine was found to be comparable in effect to benztropine mesylate, but with fewer side effects. The potential role of amantadine may be in the treatment of patients with druginduced EPS for whom medication with anticholinergic properties is contraindicated.Keywords
This publication has 8 references indexed in Scilit:
- THERAPEUTIC REVERSAL WITH BENZTROPINE IN SCHIZOPHRENICSJournal of Nervous & Mental Disease, 1975
- Effect of cholinergic and anticholinergic agents on tardive dyskinesiaJournal of Neurology, Neurosurgery & Psychiatry, 1974
- Effects of mode of management on plasma chlorpromazine in psychiatric patientsClinical Pharmacology & Therapeutics, 1973
- AMANTADINE THERAPY IN PARKINSONISMActa Neurologica Scandinavica, 1972
- Amantadine Hydrochloride Treatment of Tardive DyskinesiaNew England Journal of Medicine, 1971
- Amantadine for Dyskinesia TardaNew England Journal of Medicine, 1971
- Dyskinesia and NeurolepticsArchives of General Psychiatry, 1968
- Drug-Induced Extrapyramidal Symptoms and Their Relations to Clinical EfficacyAmerican Journal of Psychiatry, 1967